Published in Nat Rev Cancer on April 18, 2013
A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. Cell Host Microbe (2016) 1.83
O2(⋅-) and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell (2017) 1.42
Risk of cancer in patients with iron deficiency anemia: a nationwide population-based study. PLoS One (2015) 1.40
NAF-1 and mitoNEET are central to human breast cancer proliferation by maintaining mitochondrial homeostasis and promoting tumor growth. Proc Natl Acad Sci U S A (2013) 1.14
Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells. Cancer Cell (2015) 1.08
HSPB1 as a novel regulator of ferroptotic cancer cell death. Oncogene (2015) 1.07
Iron metabolism regulates p53 signaling through direct heme-p53 interaction and modulation of p53 localization, stability, and function. Cell Rep (2014) 0.99
The IRP/IRE system in vivo: insights from mouse models. Front Pharmacol (2014) 0.96
IRP2 regulates breast tumor growth. Cancer Res (2013) 0.94
Targeting cancer by binding iron: Dissecting cellular signaling pathways. Oncotarget (2015) 0.91
Hepcidin regulation in prostate and its disruption in prostate cancer. Cancer Res (2015) 0.91
Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities. Protein Cell (2014) 0.91
Iron Homeostasis in Health and Disease. Int J Mol Sci (2016) 0.89
Genetic similarity between cancers and comorbid Mendelian diseases identifies candidate driver genes. Nat Commun (2015) 0.86
Iron and cancer: recent insights. Ann N Y Acad Sci (2016) 0.86
Physiology and pathophysiology of iron in hemoglobin-associated diseases. Free Radic Biol Med (2014) 0.85
Using a biomimetic membrane surface experiment to investigate the activity of the magnetite biomineralisation protein Mms6. RSC Adv (2016) 0.84
Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation. Cancer Res (2015) 0.84
Cullin family proteins and tumorigenesis: genetic association and molecular mechanisms. J Cancer (2015) 0.84
Dietary iron enhances colonic inflammation and IL-6/IL-11-Stat3 signaling promoting colonic tumor development in mice. PLoS One (2013) 0.83
Activation of apoptosis in NAF-1-deficient human epithelial breast cancer cells. J Cell Sci (2015) 0.83
Regulators of Iron Homeostasis: New Players in Metabolism, Cell Death, and Disease. Trends Biochem Sci (2015) 0.83
Artesunate induces cell death in human cancer cells via enhancing lysosomal function and lysosomal degradation of ferritin. J Biol Chem (2014) 0.82
Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs. PLoS One (2014) 0.82
The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma. Oncotarget (2016) 0.82
Investigation of the salicylaldehyde thiosemicarbazone scaffold for inhibition of influenza virus PA endonuclease. J Biol Inorg Chem (2015) 0.80
miR-20a regulates expression of the iron exporter ferroportin in lung cancer. J Mol Med (Berl) (2015) 0.80
Cancer cells with irons in the fire. Free Radic Biol Med (2014) 0.80
Chemical tools for detecting Fe ions. J Clin Biochem Nutr (2016) 0.80
Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor (EGFR) and oncogenic signaling. J Biol Chem (2017) 0.79
A link between premenopausal iron deficiency and breast cancer malignancy. BMC Cancer (2013) 0.79
Circulating Metabolites and Survival Among Patients With Pancreatic Cancer. J Natl Cancer Inst (2016) 0.79
Oxidative stress and the homeodynamics of iron metabolism. Biomolecules (2015) 0.79
Stomach Cancer: Interconnection between the Redox State, Activity of MMP-2, MMP-9 and Stage of Tumor Growth. Cancer Microenviron (2016) 0.79
Electron paramagnetic resonance study of tumor affected bone marrow. Cancer Microenviron (2013) 0.79
Regulation of iron homeostasis by the p53-ISCU pathway. Sci Rep (2015) 0.79
Modulation of hepcidin to treat iron deregulation: potential clinical applications. Expert Rev Hematol (2015) 0.79
Myeloid zinc-finger 1 (MZF-1) suppresses prostate tumor growth through enforcing ferroportin-conducted iron egress. Oncogene (2014) 0.79
Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function. World J Gastroenterol (2016) 0.79
Breast cancer tumorigenicity is dependent on high expression levels of NAF-1 and the lability of its Fe-S clusters. Proc Natl Acad Sci U S A (2016) 0.78
Comparative evaluation of nephrotoxicity and management by macrophages of intravenous pharmaceutical iron formulations. PLoS One (2015) 0.78
Intracellular reduction/activation of a disulfide switch in thiosemicarbazone iron chelators. Metallomics (2014) 0.78
Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib. J Clin Biochem Nutr (2016) 0.78
A novel prognostic score model incorporating CDGSH iron sulfur domain2 (CISD2) predicts risk of disease progression in laryngeal squamous cell carcinoma. Oncotarget (2016) 0.78
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis. Carcinogenesis (2015) 0.78
Ferrous Iron Binding Key to Mms6 Magnetite Biomineralisation: A Mechanistic Study to Understand Magnetite Formation Using pH Titration and NMR Spectroscopy. Chemistry (2016) 0.78
Nanomedicine: An iron age for cancer therapy. Nat Nanotechnol (2016) 0.78
Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties. PLoS One (2014) 0.77
Iron, inflammation and invasion of cancer cells. Clujul Med (2015) 0.77
The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis. Carcinogenesis (2015) 0.77
Intracellular Iron Chelation Modulates the Macrophage Iron Phenotype with Consequences on Tumor Progression. PLoS One (2016) 0.77
Natural selection on HFE in Asian populations contributes to enhanced non-heme iron absorption. BMC Genet (2015) 0.77
Imaging PEG-like nanoprobes in tumor, transient ischemia, and inflammatory disease models. Bioconjug Chem (2015) 0.76
A reactivity-based probe of the intracellular labile ferrous iron pool. Nat Chem Biol (2016) 0.76
Iron alters cell survival in a mitochondria-dependent pathway in ovarian cancer cells. Biochem J (2015) 0.76
Pro-Oxidant Activity of Amine-Pyridine-Based Iron Complexes Efficiently Kills Cancer and Cancer Stem-Like Cells. PLoS One (2015) 0.76
Oxidatively damaged guanosine in white blood cells and in urine of welders: associations with exposure to welding fumes and body iron stores. Arch Toxicol (2014) 0.76
Iron addiction: a novel therapeutic target in ovarian cancer. Oncogene (2017) 0.76
Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma. World J Gastroenterol (2016) 0.75
A Novel Tumor-Activated Prodrug Strategy Targeting Ferrous Iron Is Effective in Multiple Preclinical Cancer Models. J Med Chem (2016) 0.75
The potential of deferasirox as a novel therapeutic modality in gastric cancer. World J Surg Oncol (2016) 0.75
MicroRNA-152-mediated dysregulation of hepatic transferrin receptor 1 in liver carcinogenesis. Oncotarget (2016) 0.75
Proteomic profiling reveals that collismycin A is an iron chelator. Sci Rep (2016) 0.75
Mitochondrial autophagy promotes healthy aging. Cell Cycle (2016) 0.75
Sirtuin inhibitor sirtinol is an intracellular iron chelator. Chem Commun (Camb) (2015) 0.75
Expression of Iron-Related Proteins Differentiate Non-Cancerous and Cancerous Breast Tumors. Int J Mol Sci (2017) 0.75
Ovarian endometriosis-associated stromal cells reveal persistently high affinity for iron. Redox Biol (2015) 0.75
Microwave gallium-68 radiochemistry for kinetically stable bis(thiosemicarbazone) complexes: structural investigations and cellular uptake under hypoxia. Dalton Trans (2015) 0.75
Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability. Hum Mol Genet (2016) 0.75
Iron Deprivation Induces Transcriptional Regulation of Mitochondrial Biogenesis. J Biol Chem (2016) 0.75
Desferal regulates hCtr1 and transferrin receptor expression through Sp1 and exhibits synergistic cytotoxicity with platinum drugs in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo. Oncotarget (2016) 0.75
Expression of Ferritin Light Chain (FTL) Is Elevated in Glioblastoma, and FTL Silencing Inhibits Glioblastoma Cell Proliferation via the GADD45/JNK Pathway. PLoS One (2016) 0.75
Introduction: What to Eat When You Can't Eat. Glob Adv Health Med (2014) 0.75
The heme-p53 interaction: Linking iron metabolism to p53 signaling and tumorigenesis. Mol Cell Oncol (2014) 0.75
Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism. Oncotarget (2016) 0.75
Modulation of iron metabolism by iron chelation regulates intracellular calcium and increases sensitivity to doxorubicin. Bosn J Basic Med Sci (2016) 0.75
Targeting NF-kappa B Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to Antiandrogens. Neoplasia (2017) 0.75
Effects of Anti-repulsive Guidance Molecule C (RGMc/Hemojuvelin) Antibody on Hepcidin and Iron in Mouse Liver and Tumor Xenografts. Clin Exp Pharmacol (2016) 0.75
Iron chelators target both proliferating and quiescent cancer cells. Sci Rep (2016) 0.75
B-RAF mutations are associated with increased iron regulatory protein-2 expression in colorectal tumourigenesis. Cancer Sci (2017) 0.75
The effects of a novel aliphatic-chain hydroxamate derivative WMJ-S-001 in HCT116 colorectal cancer cell death. Sci Rep (2015) 0.75
Magnetic mapping of iron in rodent spleen. Nanomedicine (2016) 0.75
Dietary strategies for improving iron status: balancing safety and efficacy. Nutr Rev (2017) 0.75
Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo. BMC Cancer (2016) 0.75
High Inorganic Phosphate Intake Promotes Tumorigenesis at Early Stages in a Mouse Model of Lung Cancer. PLoS One (2015) 0.75
Evaluation of tumorigenic potential of CeO2 and Fe2O3 engineered nanoparticles by a human cell in vitro screening model. NanoImpact (2016) 0.75
Interactions between mitoNEET and NAF-1 in cells. PLoS One (2017) 0.75
Investigating the real role of HIF-1 and HIF-2 in iron recycling by macrophages. Haematologica (2014) 0.75
Iron depletion strategy for targeted cancer therapy: utilizing the dual roles of neutrophil gelatinase-associated lipocalin protein. J Mol Model (2016) 0.75
Salinomycin kills cancer stem cells by sequestering iron in lysosomes. Nat Chem (2017) 0.75
Recent advances to accelerate re-endothelialization for vascular stents. J Tissue Eng (2017) 0.75
Usefulness of Biomarkers in Work-Related Airway Disease. Curr Treat Options Allergy (2017) 0.75
Iron imaging reveals tumor and metastasis macrophage hemosiderin deposits in breast cancer. PLoS One (2017) 0.75
Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: Expression and prognostic value. PLoS One (2017) 0.75
Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov (2017) 0.75
Mitochondria and Iron: current questions. Expert Rev Hematol (2016) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Cancer-related inflammation. Nature (2008) 34.21
Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science (2009) 32.97
Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science (2004) 19.19
Wnt signaling and cancer. Genes Dev (2000) 18.53
Nuclear factor-kappaB in cancer development and progression. Nature (2006) 18.31
Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer (2009) 11.25
Anemia of chronic disease. N Engl J Med (2005) 10.88
Wnt signalling and its impact on development and cancer. Nat Rev Cancer (2008) 8.37
Dietary supplements and mortality rate in older women: the Iowa Women's Health Study. Arch Intern Med (2011) 6.69
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer (2011) 6.32
A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature (2000) 6.01
Iron withholding: a defense against infection and neoplasia. Physiol Rev (1984) 5.54
HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev (2009) 5.24
Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci (2008) 4.24
TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia (2003) 4.17
Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science (1997) 3.94
RTEL1 maintains genomic stability by suppressing homologous recombination. Cell (2008) 3.84
Forging a field: the golden age of iron biology. Blood (2008) 3.83
Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med (1985) 3.73
Induction of sarcoma in the rat by iron-dextran complex. Br Med J (1959) 3.56
Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest (2007) 3.40
Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat Genet (2005) 3.28
Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell (2004) 3.21
Mitochondrial dysfunction leads to nuclear genome instability via an iron-sulfur cluster defect. Cell (2009) 3.00
Hepcidin and iron homeostasis. Biochim Biophys Acta (2012) 2.96
The DNA repair helicases XPD and FancJ have essential iron-sulfur domains. Mol Cell (2006) 2.61
Body iron stores and the risk of cancer. N Engl J Med (1988) 2.61
Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem (1997) 2.58
Iron and colorectal cancer risk: human studies. Nutr Rev (2001) 2.56
HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J Clin Invest (2009) 2.47
MMS19 assembles iron-sulfur proteins required for DNA metabolism and genomic integrity. Science (2012) 2.46
A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A (2006) 2.36
Haem, not protein or inorganic iron, is responsible for endogenous intestinal N-nitrosation arising from red meat. Cancer Res (2003) 2.30
Eukaryotic DNA polymerases require an iron-sulfur cluster for the formation of active complexes. Nat Chem Biol (2011) 2.20
Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology (2010) 2.17
Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. Science (1999) 2.17
The molecular cloning and characterization of murine ferritin heavy chain, a tumor necrosis factor-inducible gene. J Biol Chem (1988) 2.15
The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res (2005) 2.14
The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell (2011) 2.12
The role of mitochondria in cellular iron-sulfur protein biogenesis and iron metabolism. Biochim Biophys Acta (2012) 2.09
Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem (2004) 2.09
Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metab (2009) 2.09
Iron traffics in circulation bound to a siderocalin (Ngal)-catechol complex. Nat Chem Biol (2010) 2.06
In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood (2010) 2.03
Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood (2010) 2.02
Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc Natl Acad Sci U S A (2010) 1.99
Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood (2009) 1.99
Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood (2008) 1.97
Iron-regulatory proteins limit hypoxia-inducible factor-2alpha expression in iron deficiency. Nat Struct Mol Biol (2007) 1.96
Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med (2010) 1.94
An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res (2011) 1.91
Overexpression of wild type and mutated human ferritin H-chain in HeLa cells: in vivo role of ferritin ferroxidase activity. J Biol Chem (2000) 1.88
Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat (2007) 1.85
A mammalian siderophore synthesized by an enzyme with a bacterial homolog involved in enterobactin production. Cell (2010) 1.85
Serum ferritin: Past, present and future. Biochim Biophys Acta (2010) 1.80
Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J Biol Chem (1999) 1.80
Previously uncharacterized isoforms of divalent metal transporter (DMT)-1: implications for regulation and cellular function. Proc Natl Acad Sci U S A (2002) 1.77
HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology (2010) 1.76
Identification of a hypoxia response element in the transferrin receptor gene. J Biol Chem (1999) 1.72
The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications. FASEB J (2010) 1.68
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol (2010) 1.66
Differential regulation of iron homeostasis during human macrophage polarized activation. Eur J Immunol (2010) 1.64
The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta (2011) 1.64
Role for NF-kappa B in the regulation of ferritin H by tumor necrosis factor-alpha. J Biol Chem (1995) 1.61
Iron regulatory proteins are essential for intestinal function and control key iron absorption molecules in the duodenum. Cell Metab (2008) 1.54
Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth: Otto Warburg revisited. J Biol Chem (2005) 1.45
Antitumor agents. 250. Design and synthesis of new curcumin analogues as potential anti-prostate cancer agents. J Med Chem (2006) 1.42
Targeted disruption of hepatic frataxin expression causes impaired mitochondrial function, decreased life span and tumor growth in mice. Hum Mol Genet (2005) 1.40
The iron chelators Dp44mT and DFO inhibit TGF-β-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). J Biol Chem (2012) 1.38
Polarization dictates iron handling by inflammatory and alternatively activated macrophages. Haematologica (2010) 1.36
Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J Biol Chem (2000) 1.35
Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci U S A (2009) 1.34
Dietary iron supplementation enhances DSS-induced colitis and associated colorectal carcinoma development in mice. Dig Dis Sci (2002) 1.34
Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology (2003) 1.34
Damage to the DNA bases in mammalian chromatin by hydrogen peroxide in the presence of ferric and cupric ions. Arch Biochem Biophys (1991) 1.31
Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. J Natl Cancer Inst (1985) 1.31
Body iron stores and risk of cancer. Int J Cancer (1994) 1.31
Ectopic expression of neutrophil gelatinase-associated lipocalin suppresses the invasion and liver metastasis of colon cancer cells. Int J Cancer (2006) 1.30
Ferroportin-mediated iron transport: expression and regulation. Biochim Biophys Acta (2012) 1.27
Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: possible regulation mechanism. Biochem Biophys Res Commun (1983) 1.27
Mechanisms of free radical-induced damage to DNA. Free Radic Res (2012) 1.24
DNA2 and EXO1 in replication-coupled, homology-directed repair and in the interplay between HDR and the FA/BRCA network. Cell Cycle (2012) 1.23
Crystal structure of human pirin: an iron-binding nuclear protein and transcription cofactor. J Biol Chem (2003) 1.23
Nephrotoxicity and renal cell carcinoma after use of iron- and aluminum-nitrilotriacetate complexes in rats. J Natl Cancer Inst (1986) 1.23
Modulation of iron transport proteins in human colorectal carcinogenesis. Gut (2006) 1.23
Role of ferritin alterations in human breast cancer cells. Breast Cancer Res Treat (2011) 1.22
Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. Ann Epidemiol (2004) 1.22
Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology (2001) 1.21
Analysis of the biologic functions of H- and L-ferritins in HeLa cells by transfection with siRNAs and cDNAs: evidence for a proliferative role of L-ferritin. Blood (2003) 1.20
In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Cancer Res (2004) 1.20
Disruption of the Lcn2 gene in mice suppresses primary mammary tumor formation but does not decrease lung metastasis. Proc Natl Acad Sci U S A (2010) 1.19
A role for iron in Wnt signalling. Oncogene (2007) 1.19
Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice. Cancer Res (1988) 1.18
Hypoxia-inducible factor-2α activation promotes colorectal cancer progression by dysregulating iron homeostasis. Cancer Res (2012) 1.17
A systems biology view of cancer. Biochim Biophys Acta (2009) 1.17
Iron chelation in the biological activity of curcumin. Free Radic Biol Med (2006) 1.17
Iron chelators for the treatment of cancer. Curr Med Chem (2012) 1.16
DNA base modifications in renal chromatin of Wistar rats treated with a renal carcinogen, ferric nitrilotriacetate. Int J Cancer (1994) 1.15
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell (2004) 3.21
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol (2012) 2.34
Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc Natl Acad Sci U S A (2010) 1.99
Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood (2008) 1.97
Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med (2010) 1.94
An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res (2011) 1.91
Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging (2013) 1.82
Serum ferritin: Past, present and future. Biochim Biophys Acta (2010) 1.80
Iron chelators in cancer chemotherapy. Curr Top Med Chem (2004) 1.61
TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis. J Exp Med (2005) 1.52
Prostate cancer risk associated loci in African Americans. Cancer Epidemiol Biomarkers Prev (2009) 1.49
Ferritin for the clinician. Blood Rev (2008) 1.46
Demand for continuing medical education programs on cancer care among primary care physicians in North Carolina. N C Med J (2004) 1.46
Long-term survival following a single treatment of kidney tumors with multiwalled carbon nanotubes and near-infrared radiation. Proc Natl Acad Sci U S A (2009) 1.41
Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci U S A (2009) 1.34
Phase II trial of radio frequency ablation of renal cancer: evaluation of the kill zone. J Urol (2002) 1.30
Ironing out cancer. Cancer Res (2011) 1.25
Nrf2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones. J Biol Chem (2002) 1.23
A systems biology view of cancer. Biochim Biophys Acta (2009) 1.17
Iron chelation in the biological activity of curcumin. Free Radic Biol Med (2006) 1.17
The role of iron chelation in cancer therapy. Curr Med Chem (2003) 1.15
Excess capacity of the iron regulatory protein system. J Biol Chem (2007) 1.14
Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol (2009) 1.14
Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress. J Neurosci Res (2003) 1.13
Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. Am Heart J (2005) 1.12
The transplant iron score as a predictor of stem cell transplant survival. J Hematol Oncol (2009) 1.10
Bioinformatics tools for cancer metabolomics. Metabolomics (2011) 1.10
Thermal ablation therapeutics based on CN(x) multi-walled nanotubes. Int J Nanomedicine (2007) 1.09
Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation. Blood (2005) 1.08
Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. Circ Cardiovasc Imaging (2010) 1.05
Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res (2009) 1.04
A general map of iron metabolism and tissue-specific subnetworks. Mol Biosyst (2009) 1.02
A human bone morphogenetic protein antagonist is down-regulated in renal cancer. Mol Biol Cell (2007) 1.01
Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res (2005) 1.01
Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin. Am J Physiol Lung Cell Mol Physiol (2008) 1.01
Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology (2006) 0.97
The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy. Biomaterials (2012) 0.97
Synthetic and natural iron chelators: therapeutic potential and clinical use. Future Med Chem (2009) 0.94
IRP2 regulates breast tumor growth. Cancer Res (2013) 0.94
Activation of caspase pathways during iron chelator-mediated apoptosis. J Biol Chem (2002) 0.94
Development of iron-containing multiwalled carbon nanotubes for MR-guided laser-induced thermotherapy. Nanomedicine (Lond) (2011) 0.92
Serum levels of phytanic acid are associated with prostate cancer risk. Prostate (2005) 0.92
Determinants of the thrombogenic potential of multiwalled carbon nanotubes. Biomaterials (2011) 0.92
Post-transcriptional modulation of iron homeostasis during p53-dependent growth arrest. J Biol Chem (2008) 0.90
Ferritin binds to light chain of human H-kininogen and inhibits kallikrein-mediated bradykinin release. Biochem J (2002) 0.89
Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis. Prostate (2012) 0.89
Iron uptake mediated by binding of H-ferritin to the TIM-2 receptor in mouse cells. PLoS One (2011) 0.89
SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer. Breast Cancer Res Treat (2010) 0.89
Tissue-specific expression of ferritin H regulates cellular iron homoeostasis in vivo. Biochem J (2006) 0.89
Health system correlates of receipt of radiation therapy after breast-conserving surgery: a study of low-income Medicaid-enrolled women. Am J Manag Care (2008) 0.88
Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Biochem Pharmacol (2004) 0.88
A novel cytostatic form of autophagy in sensitization of non-small cell lung cancer cells to radiation by vitamin D and the vitamin D analog, EB 1089. Autophagy (2014) 0.88
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother Pharmacol (2007) 0.87
Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1. Prostate (2012) 0.86
Prostate cancer and bone metastases: medical treatment. Clin Orthop Relat Res (2003) 0.85
Ferritin blocks inhibitory effects of two-chain high molecular weight kininogen (HKa) on adhesion and survival signaling in endothelial cells. PLoS One (2012) 0.84
Ferritin regulation by oxidants and chemopreventive xenobiotics. Adv Enzyme Regul (2003) 0.83
Ferritin H induction by histone deacetylase inhibitors. Biochem Pharmacol (2010) 0.82
Loss of heterozygosity and SOSTDC1 in adult and pediatric renal tumors. J Exp Clin Cancer Res (2010) 0.82
Ferritin H is a novel marker of early erythroid precursors and macrophages. Histopathology (2013) 0.81
Oxathiolene oxides: a novel family of compounds that induce ferritin, glutathione S-transferase, and other proteins of the phase II response. Biochem Pharmacol (2003) 0.81
Bone metastases in prostate cancer: a targeted approach. Curr Opin Oncol (2007) 0.81
Cellular iron metabolism in prognosis and therapy of breast cancer. Crit Rev Oncog (2013) 0.80
Preliminary evaluation of the cytotoxicity of a series of tris-2-aminoethylamine (Tren) based hexadentate heterocyclic donor agents. Bioorg Med Chem (2005) 0.80
Synthesis and potent antitumor activities of novel 1,3,5-cis,cis-triaminocyclohexane N-pyridyl derivatives. J Med Chem (2004) 0.79
Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. Cancer (2006) 0.79
Weekly doxorubicin increases coronary arteriolar wall and adventitial thickness. PLoS One (2013) 0.79
Synthesis of 1,3,5-cis,cis-triaminocyclohexane N-pyridyl derivatives as potential antitumor agents. J Org Chem (2002) 0.78
Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. Urology (2004) 0.77
Radiofrequency ablation of isolated local recurrence of renal cell carcinoma after radical nephrectomy. AJR Am J Roentgenol (2003) 0.77
Coordinate inhibition of cytokine-mediated induction of ferritin H, manganese superoxide dismutase, and interleukin-6 by the adenovirus E1A oncogene. J Biol Chem (2006) 0.76
Application of circuit simulation method for differential modeling of TIM-2 iron uptake and metabolism in mouse kidney cells. Front Physiol (2013) 0.76
Influence of ligand structure on Fe(II) spin-state and redox rate in cytotoxic tripodal chelators. J Inorg Biochem (2007) 0.75
N-picolyl derivatives of Kemp's triamine as potential antitumor agents: a preliminary investigation. J Med Chem (2005) 0.75
The high-molecular-weight kininogen domain 5 is an intrinsically unstructured protein and its interaction with ferritin is metal mediated. Protein Sci (2014) 0.75
Use of green fluorescent protein to measure tumor growth in an implanted bladder tumor model. J Urol (2002) 0.75
Questions without answers. Curr Opin Oncol (2005) 0.75